Chemed Corporation's stock undervalued by 23% according to DCF analysis
Summary
Chemed Corporation’s stock is currently priced at $473, which is considered to be 23% undervalued compared to its estimated intrinsic value of $614 based on a DCF analysis. This analysis estimates the company’s total equity value to be approximately $8.9 billion, with a terminal value calculation of $12 billion. Investors are advised to consider the assumptions behind the DCF model as changes in inputs can significantly alter the valuation. Simplywall
Impact Analysis
- Business Overview Analysis
- Chemed Corporation operates in the healthcare sector, providing hospice care and plumbing services, which are its core business models and revenue streams. The company’s market position is strong, given its well-established brands in both sectors. However, recent changes in shareholdings indicate mixed investor sentiment.
- Significant events: Reports show varying changes in institutional holdings, with some firms increasing and others decreasing their positions, which suggests differing views on the company’s future performance. Market Beat+ 4
- Financial Statement Analysis
- The DCF analysis suggests the company is undervalued, indicating potential for future price appreciation if the market aligns with the intrinsic value estimation. The EPS forecast of $21.43 for the fiscal year supports a positive outlook. Market Beat+ 2
- Investor caution is advised due to potential variations in valuation with changes in DCF model assumptions. This highlights the importance of understanding the inputs used in the valuation model.Simplywall
Overall, Chemed Corporation appears undervalued by traditional valuation metrics, but investor sentiment is mixed, as seen in recent changes to institutional holdings. The upcoming financial results release on July 29 could provide further insights into the company’s performance and guide future valuation adjustments. Reuters
